• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta biomaterialia >In vivo inhibition of hypertrophic scars by implantable ginsenoside-Rg3-loaded electrospun fibrous membranes
【24h】

In vivo inhibition of hypertrophic scars by implantable ginsenoside-Rg3-loaded electrospun fibrous membranes

机译：植入人参皂甙-Rg3的电纺纤维膜对肥厚性瘢痕的体内抑制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clinically, hypertrophic scarring (HS) is a major concern for patients and has been a challenge for surgeons, as there is a lack of treatments that can intervene early in the formation of HS. This study reports on a Chinese drug, 20(R)-ginsenoside Rg3 (GS-Rg3), which can inhibit in vivo the early formation of HS and later HS hyperplasia by inducing the apoptosis of fibroblasts, inhibiting inflammation and down-regulating VEGF expression. Implantable biodegradable GS-Rg3-loaded poly(l-lactide) (PLA) fibrous membranes were successfully fabricated using co-electrospinning technology to control drug release and improve drug utilization. The in vivo releasing time of GS-Rg3 lasts for 3 months, and the drug concentration released in rabbits can be controlled by varying the drug content of the electrospun fibers. Histological observations of HE staining indicate that GS-Rg3/PLA significantly inhibits the HS formation, with obvious improvements in terms of dermis layer thickness, epidermis layer thickness and fibroblast proliferation. The results of immunohistochemistry staining and Masson's trichrome staining demonstrate that GS-Rg3/PLA electrospun fibrous membranes significantly inhibit HS formation, with decreased expression of collagen fibers and microvessels. VEGF protein levels are much lower in the group treated with GS-Rg3/PLA eletrospun membranes compared with other groups. These results demonstrate that GS-Rg3 is a novel drug, capable of inhibiting the early formation of HS and later HS hyperplasia. GS-Rg3/PLA electrospun membrane is a very promising new treatment for early and long-term treatment of HS.
机译：在临床上，肥厚性瘢痕形成（HS）是患者的主要问题，并且由于缺乏可在HS形成早期进行干预的治疗方法，因此一直是外科医生面临的挑战。这项研究报告了一种中药20（R）-人参皂苷Rg3（GS-Rg3），该药物可通过诱导成纤维细胞凋亡，抑制炎症反应和下调VEGF表达来抑制体内HS的早期形成和HS增生。 。使用共电纺丝技术成功地制备了可植入的可生物降解的负载GS-Rg3的聚（l-丙交酯）（PLA）纤维膜，以控制药物释放并提高药物利用率。 GS-Rg3的体内释放时间持续3个月，可通过改变电纺纤维的药物含量来控制兔子释放的药物浓度。 HE染色的组织学观察表明，GS-Rg3 / PLA显着抑制HS的形成，在真皮层厚度，表皮层厚度和成纤维细胞增殖方面有明显改善。免疫组织化学染色和Masson三色染色的结果表明，GS-Rg3 / PLA电纺纤维膜显着抑制HS的形成，胶原纤维和微血管的表达减少。与其他组相比，用GS-Rg3 / PLA电纺丝膜处理的组中的VEGF蛋白水平要低得多。这些结果表明，GS-Rg3是一种新型药物，能够抑制HS的早期形成和随后的HS增生。 GS-Rg3 / PLA电纺膜是用于HS早期和长期治疗的非常有前景的新治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号